Alpha DNA Investment Management’s Nutanix NTNX Stock Holding History

Alpha DNA Investment Management’s Portfolio NTNX Stock Details NTNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,944	Closed	-$522K	–	229
2023 Q4	$522K	Sell	10,944 -5,053	-32%	-$204K	0.2%	118
2023 Q3	$558K	Sell	15,997 -13,349	-45%	-$419K	0.23%	110
2023 Q2	$823K	Sell	29,346 -11,741	-29%	-$312K	0.27%	88
2023 Q1	$1.07M	Sell	41,087 -1,176	-3%	-$31.8K	0.32%	94
2022 Q4	$1.1M	Buy	+42,263	New	+$1.15M	0.39%	75
2021 Q4	–	Sell	-36,362	Closed	-$1.37M	–	134
2021 Q3	$1.37M	Buy	36,362 +1,289	+4%	+$48.7K	0.93%	76
2021 Q2	$1.34M	Buy	35,073 +9,717	+38%	+$303K	0.91%	82
2021 Q1	$673K	Buy	25,356 +25,339	+149,053%	+$771K	0.77%	41
2020 Q4	$0	Buy	+17	New	+$461	﹤0.01%	617

Other funds holding NTNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpha DNA Investment Management's NTNX Position: Q1 2024 in Review

Alpha DNA Investment Management sold out of Nutanix (NTNX) in Q1 2024, closing a stake of 10,944 shares — an estimated $522K sold.

Alpha DNA Investment Management first reported a position in NTNX in Q4 2020 and held it in 9 quarters. The position peaked at $1.37M in Q3 2021. 473 funds tracked by Wall St. Rank hold NTNX as of Q1 2024.

Alpha DNA Investment Management reported no remaining Nutanix position as of Q1 2024 after selling out during the quarter.
Alpha DNA Investment Management sold 10,944 Nutanix shares in Q1 2024, an estimated $522K.
Alpha DNA Investment Management first reported a position in Nutanix in Q4 2020 and held it in 9 quarters.
Alpha DNA Investment Management's Nutanix position peaked at $1.37M in Q3 2021.
473 funds tracked by Wall St. Rank held Nutanix as of Q1 2024.

Based on Alpha DNA Investment Management's 13F filing for Q1 2024, filed 15 May 2024.